vs
Side-by-side financial comparison of Brookfield Asset Management Ltd. (BAM) and Jazz Pharmaceuticals plc (JAZZ). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.1× Brookfield Asset Management Ltd.). Brookfield Asset Management Ltd. runs the higher net margin — 56.7% vs 17.0%, a 39.7% gap on every dollar of revenue.
Brookfield Asset Management Ltd. is a Canadian-American alternative asset manager. The company was founded in December 2022 as a spin-off of the asset management operations of Brookfield Corporation, and manages investments across real estate, infrastructure, renewable energy, private equity, and credit markets globally.
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
BAM vs JAZZ — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $615.0M | $203.5M |
| Gross Margin | — | — |
| Operating Margin | 84.2% | 21.2% |
| Net Margin | 56.7% | 17.0% |
| Revenue YoY | — | 10.1% |
| Net Profit YoY | — | 6.5% |
| EPS (diluted) | — | $3.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $974.0M | $1.1B | ||
| Q2 25 | $931.0M | $1.0B | ||
| Q1 25 | $954.0M | $897.8M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | $873.0M | $1.1B | ||
| Q2 24 | $821.0M | $1.0B | ||
| Q1 24 | $786.0M | $902.0M |
| Q4 25 | $615.0M | $203.5M | ||
| Q3 25 | $692.0M | $251.4M | ||
| Q2 25 | $584.0M | $-718.5M | ||
| Q1 25 | $507.0M | $-92.5M | ||
| Q4 24 | — | $191.1M | ||
| Q3 24 | $537.0M | $215.1M | ||
| Q2 24 | $124.0M | $168.6M | ||
| Q1 24 | $373.0M | $-14.6M |
| Q4 25 | 84.2% | 21.2% | ||
| Q3 25 | 79.1% | 5.1% | ||
| Q2 25 | 70.8% | -65.6% | ||
| Q1 25 | 61.0% | -6.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | 72.5% | 24.7% | ||
| Q2 24 | 80.4% | 19.5% | ||
| Q1 24 | 56.5% | 7.3% |
| Q4 25 | 56.7% | 17.0% | ||
| Q3 25 | 71.0% | 22.3% | ||
| Q2 25 | 62.7% | -68.7% | ||
| Q1 25 | 53.1% | -10.3% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | 61.5% | 20.4% | ||
| Q2 24 | 15.1% | 16.5% | ||
| Q1 24 | 47.5% | -1.6% |
| Q4 25 | — | $3.34 | ||
| Q3 25 | — | $4.08 | ||
| Q2 25 | — | $-11.74 | ||
| Q1 25 | — | $-1.52 | ||
| Q4 24 | — | $2.97 | ||
| Q3 24 | — | $3.42 | ||
| Q2 24 | — | $2.49 | ||
| Q1 24 | — | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.6B | $1.4B |
| Total DebtLower is stronger | — | $5.4B |
| Stockholders' EquityBook value | $8.9B | $4.3B |
| Total Assets | $17.0B | $11.7B |
| Debt / EquityLower = less leverage | — | 1.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $1.4B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $480.0M | $1.2B | ||
| Q1 25 | $332.0M | $1.9B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | $10.0M | $1.4B | ||
| Q1 24 | — | $1.4B |
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
| Q4 25 | $8.9B | $4.3B | ||
| Q3 25 | $8.5B | $4.0B | ||
| Q2 25 | $8.5B | $3.7B | ||
| Q1 25 | $8.5B | $4.2B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | $9.0B | $4.2B | ||
| Q2 24 | $3.2B | $3.8B | ||
| Q1 24 | $2.2B | $3.7B |
| Q4 25 | $17.0B | $11.7B | ||
| Q3 25 | $16.5B | $11.4B | ||
| Q2 25 | $16.1B | $10.9B | ||
| Q1 25 | $15.0B | $11.5B | ||
| Q4 24 | — | $12.0B | ||
| Q3 24 | — | $12.3B | ||
| Q2 24 | $4.2B | $11.4B | ||
| Q1 24 | — | $11.3B |
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $562.0M | $362.5M |
| Free Cash FlowOCF − Capex | — | $345.8M |
| FCF MarginFCF / Revenue | — | 28.9% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | 0.91× | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $562.0M | $362.5M | ||
| Q3 25 | $745.0M | $474.6M | ||
| Q2 25 | $529.0M | $88.9M | ||
| Q1 25 | $265.0M | $429.8M | ||
| Q4 24 | — | $398.6M | ||
| Q3 24 | $567.0M | $398.7M | ||
| Q2 24 | $159.0M | $331.4M | ||
| Q1 24 | $516.0M | $267.2M |
| Q4 25 | — | $345.8M | ||
| Q3 25 | — | $459.4M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $415.9M | ||
| Q4 24 | — | $385.3M | ||
| Q3 24 | — | $388.0M | ||
| Q2 24 | — | $324.3M | ||
| Q1 24 | — | $260.3M |
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 40.8% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.8% | ||
| Q2 24 | — | 31.7% | ||
| Q1 24 | — | 28.9% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | 0.91× | 1.78× | ||
| Q3 25 | 1.08× | 1.89× | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | 1.06× | 1.85× | ||
| Q2 24 | 1.28× | 1.97× | ||
| Q1 24 | 1.38× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAM
| Incentive Fees | $452.0M | 42% |
| Infrastruture | $332.0M | 31% |
| Private Equity | $174.0M | 16% |
| Renewable Power And Transition | $66.0M | 6% |
| Other | $47.0M | 4% |
| Management And Advisory Fees | $14.0M | 1% |
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
